

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for treating inflammatory disease of the external segment or the anterior segment of the eye, which comprises administering to the eye an aqueous eye drop ~~consisting essentially of comprising~~ 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate ~~thereof~~ thereof, and at least one organic amine selected from the group consisting of ~~an amino acid, an alkanolamine, a piperazine and an aminoalkylsulfonic acid~~ arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cysteine, phenylalanine, isoleucine, monoethanolamine, diethanolamine, triethanolamine, trometamol, (2-4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid, 1,4-bis(2-sulfoethyl)-piperazine, ethylene diamine, trimethylene diamine, N,N'-bis(3-sulfopropyl)ethylene diamine, aminomethylsulfonic acid and aminoethylsulfonic acid once a day, and maintaining a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor of the eye.

2. (Cancelled)

3. (Previously presented) The method according to claim 1, wherein the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof in the aqueous eye drop is 0.01 to 0.5w/v%.

4. (Cancelled)

5. (Currently amended) The method according to claim 1, wherein the organic amine is an amino acid ~~selected from the group consisting of~~ arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cysteine, phenylalanine and isoleucine, and its concentration is 0.35 to 5w/v%.

6. (Currently amended) The method according to claim 1, wherein the organic amine is ~~an~~ alkanolamine ~~selected from the group consisting of~~ monoethanolamine, triethanolamine and trometamol, and its concentration is 0.15 to 0.95w/v%.

7. (Currently amended) The method according to claim 1, wherein the ~~alkanolamine~~ organic amine is trometamol.

8. (Cancelled)

9. (Currently amended) The method according to claim 1, wherein the organic amine is a ~~piperazine-2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or 1,4-bis(2-sulfoethyl) piperazine,~~ and it is contained at a concentration of 0.05 to 5w/v% in the aqueous eye drop.

10. (Currently amended) The method according to claim 1, wherein the organic amine is an ~~aminoalkylsulfonic acid-aminomethylsulfonic acid or aminoethylsulfonic acid,~~ and its concentration is 0.05 to 5w/v%.

11. (Currently amended) The method according to claim 10, wherein the ~~aminoalkylsulfonic acid-organic amine~~ is aminoethylsulfonic acid.

12-35. (Cancelled)